Phio Pharmaceuticals Corp. current report, 01 June 2015

Full document

Business Context and Reporting Period

This Form 8-K filing by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) covers the 2015 Annual Meeting of Stockholders held on June 1, 2015. The report details the outcomes of shareholder votes regarding corporate governance and auditor ratification.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on corporate events rather than financial performance.

Material Changes

No material financial changes are reported in this filing. The primary event is the successful completion of the Annual Meeting where all binding matters were approved by stockholders.

Guidance, Outlook, and Voting Results

The filing provides specific voting results for the Annual Meeting:

  • Shareholder Participation: 23,965,729 shares were present or represented by proxy out of 31,221,598 shares entitled to vote.
  • Election of Directors: All five nominees were elected. There were 17,448,290 broker non-votes for each director.
    • Geert Cauwenbergh: 6,155,424 votes for, 362,015 withheld.
    • Robert J. Bitterman: 6,181,302 votes for, 336,137 withheld.
    • Keith L. Brownlie: 6,156,456 votes for, 360,983 withheld.
    • H. Paul Dorman: 6,153,834 votes for, 363,605 withheld.
    • Curtis A. Lockshin: 6,157,240 votes for, 360,199 withheld.
  • Ratification of Auditors: Stockholders ratified BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015.
    • Votes For: 23,139,365
    • Votes Against: 555,566
    • Abstentions: 270,798
    • Broker Non-Votes: 0

The filing contains no management commentary on future guidance, risks, or contingencies.

Investor Verification Checklist

  • Verify the company name discrepancy: The filing header lists "RXi Pharmaceuticals Corporation," while the request metadata lists "Phio Pharmaceuticals Corp."
  • Confirm the total number of shares entitled to vote (31,221,598) against the company's latest 10-K or 10-Q.
  • Review the significant number of broker non-votes (17,448,290) regarding the director elections to understand voting power distribution.
  • Check subsequent filings for the financial results of the fiscal year ending December 31, 2015, as this 8-K does not contain financial data.